Berenberg Bank set a CHF 88 price target on Novartis AG (VTX:NOVN) in a report issued on Monday. The firm currently has a neutral rating on the stock.

NOVN has been the subject of a number of other research reports. Morgan Stanley set a CHF 88 price objective on Novartis AG and gave the company a buy rating in a research report on Friday, October 20th. UBS AG set a CHF 78 price objective on Novartis AG and gave the company a neutral rating in a research report on Monday, October 23rd. Kepler Capital Markets set a CHF 87 price objective on Novartis AG and gave the company a buy rating in a research report on Monday, August 28th. Jefferies Group LLC set a CHF 97 price objective on Novartis AG and gave the company a buy rating in a research report on Monday, July 24th. Finally, HSBC Holdings plc set a CHF 90 price objective on Novartis AG and gave the company a buy rating in a research report on Thursday, September 7th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of CHF 86.10.

Shares of Novartis AG (NOVN) traded up 0.98% during midday trading on Monday, reaching CHK 82.40. The company’s stock had a trading volume of 2,471,339 shares. Novartis AG has a 52 week low of CHK 67.40 and a 52 week high of CHK 85.40. The stock has a 50-day moving average price of CHK 83.24 and a 200 day moving average price of CHK 80.41. The stock has a market capitalization of CHK 193.05 billion and a PE ratio of 30.08.

COPYRIGHT VIOLATION WARNING: “Novartis AG (NOVN) Given a CHF 88 Price Target at Berenberg Bank” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://theolympiareport.com/2017/10/31/novartis-ag-novn-given-a-chf-88-price-target-at-berenberg-bank.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.